Tanaz Meghjani

1 week ago | news.bloomberglaw.com | Robert Langreth |Tanaz Meghjani |Rachael Dottle

For the full experience visit: Cancer Drugs Cost More Than Ever. They Often Don’t Extend LivesThe moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew the go-to drug in many cases was Pfizer Inc.’s Ibrance. She learned it might cost her mother, who lived on a fixed income, around $10,000 out of pocket annually.

1 week ago | news.bloomberglaw.com | Robert Langreth |Tanaz Meghjani |Rachael Dottle

For the full experience visit: Cancer Drugs Cost More Than Ever. They Often Don’t Extend LivesThe moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew the go-to drug in many cases was Pfizer Inc.’s Ibrance. She learned it might cost her mother, who lived on a fixed income, around $10,000 out of pocket annually.

1 week ago | bloomberg.com | Robert Langreth |Tanaz Meghjani |Rachael Dottle

Industries | The Big Take By Robert Langreth Tanaz Meghjani Rachael Dottle May 28, 2025 The moment she heard that her mother, then 67, had advanced breast cancer, Stacie Dusetzina began hunting for potential treatments. A cancer policy researcher at Vanderbilt University, Dusetzina knew the go-to drug in many cases was Pfizer Inc.’s Ibrance. She learned it might cost her mother, who lived on a fixed income, around $10,000 out of pocket annually.

3 weeks ago | news.bloombergtax.com | Tanaz Meghjani |Biz Carson |Madison Muller

XYour Choices Regarding Cookies and IdentifiersWe and our 150 third party partners use cookies and similar technologies ("Cookies") and hashed identifiers (e.g., a hashed version of your name, email address or phone number) to help us identify you on our site and third-party sites and to process certain information, such as your IP address and digital identifiers, to analyze site usage and provide you with relevant advertisements and content.

3 weeks ago | news.bloomberglaw.com | Tanaz Meghjani |Biz Carson |Madison Muller

The success of Eli Lilly & Co.'s weight-loss and diabetes drugs has pushed the company’s stock to new heights, helping the founding family’s endowment become the largest private foundation in the US. At the end of 2024, the Lilly Endowment had $79.9 billion in assets, according to filings released Friday. That’s about a 29% jump from a year earlier, topping the $77.2 billion of the Gates Foundation, which had held the top spot for several years.